293 related articles for article (PubMed ID: 31221073)
1. [Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
Korotaeva ES; Koroleva LY; Kovaleva GV; Kuzmenko EA; Nosov VP
Kardiologiia; 2019 Jun; 59(5S):27-36. PubMed ID: 31221073
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
Xin YG; Zhang HS; Li YZ; Guan QG; Guo L; Gao Y; Yu HJ; Zhang XG; Xu F; Zhang YL; Jia DL; Sun YX; Qi GX; Tian W
Int J Cardiol; 2017 Feb; 228():275-279. PubMed ID: 27865197
[TBL] [Abstract][Full Text] [Related]
5. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study.
Gao CZ; Ma QQ; Wu J; Liu R; Wang F; Bai J; Yang XJ; Fu Q; Wei P
Cell Physiol Biochem; 2018; 48(1):385-396. PubMed ID: 30016801
[TBL] [Abstract][Full Text] [Related]
8. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
Zhao X; Ai G; Qiu M; Wang X; Zhang L; Yang X; Liu Y; Xu P; Zhang J; Gu C; Zhou M; Hao Y; Zhao D; Han Y;
Int J Cardiol; 2020 Jul; 310():1-8. PubMed ID: 32307186
[TBL] [Abstract][Full Text] [Related]
11. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of ticagrelor versus clopidogrel in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention].
Na K; Li MY; Qiu MH; Li J; Liu R; Li Y; Han YL
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Nov; 49(11):1117-1123. PubMed ID: 34775722
[No Abstract] [Full Text] [Related]
13. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
14. [Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
Xia JG; Qu Y; Hu SD; Xu J; Yin CL; Xu D
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 47(3):494-8. PubMed ID: 26080882
[TBL] [Abstract][Full Text] [Related]
15. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Wang HY; Li Y; Xu XM; Li J; Han YL
Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210
[TBL] [Abstract][Full Text] [Related]
16. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
18. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
[TBL] [Abstract][Full Text] [Related]
19. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Xu S; Liang Y; Chen Y; Gao H; Tan Z; Wang Q; Liu Y; Zhu B; Tao F; Wang Q; Zhao S; Yang L; Zhang Y; Wang Z; Han P; Chen Y; Zhang A; Li C; Lian K
Drugs Aging; 2022 Sep; 39(9):695-703. PubMed ID: 35995912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
